Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition
Fig 5
Vaccine-induced plasmablasts and risk of SIVmac251 acquisition.
Comparison of the vaccine-induced variations in the frequency of plasmablasts (PBs) at week 0 and week 25. Total PBs in (A) NYVAC-SIV and (B) ALVAC-SIV groups. Percent of (C) CXCR3+, and (D) α4β7+ PBs in the NYVAC-SIV group. Percent of (E) CXCR3+ and (F) α4β7+ PBs in the ALVAC-SIV group. (G–H) Survival curve showing significant protection in animals with above average increases in levels of α4β7+ PBs (from baseline levels) and time to acquisition compared to controls in the (G) ALVAC-group and (H) in the NYVAC group. (I) GSEA analysis of the transcriptomic profile of the ALVAC-SIV/gp120 animals at week 25 revealed an enrichment of plasma cell markers among genes associated with lower risk of SIV acquisition. (J) The SLEA method was used to summarize plasma cell markers for each subject. The scatterplot shows average plasma cell markers as a function of the frequency of α4β7+ PBs in ALVAC-SIV/gp120 treated animals at week 25. The size of the dots is proportional to the number of SIV challenges to infection. The grey area indicates the 95% confidence region of this correlation.
